Key Metrics
CiteScore 

716.2
Impact Factor 

>= 25
SNIP 

173.93
Recommended pre-submission checks
Powered by 

Ca-A Cancer Journal for Clinicians Journal Specifications
| Overview | |
| Publisher | WILEY |
| Language | English |
| Frequency | Bi-monthly |
| General Details | |
| Language | English |
| Frequency | Bi-monthly |
| Publication Start Year | 1950 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Ca-A Cancer Journal for Clinicians ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Ca-A Cancer Journal for Clinicians
Radiotherapy followed by adjuvant temozolomide improves survival for patients with aggressive IDH-mutated anaplastic glioma.
- 1 Mar 2026
- CA: a cancer journal for clinicians
Targeting tumor suppressor gene co-mutations in EGFR-mutant nonsmall cell lung cancer: How ACROSS2 sharpens the case for early intensification.
- 1 Mar 2026
- CA: a cancer journal for clinicians
Ethical considerations of genetic and genomic testing in pediatric oncology: A narrative review.
- 1 Mar 2026
- CA: a cancer journal for clinicians
Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study.
- 1 Mar 2026
- CA: a cancer journal for clinicians
Nonpharmacologic interventions for managing distress, anxiety, and depression for patients with cancer and their family caregivers: A systematic review and meta-analysis.
- 1 Mar 2026
- CA: a cancer journal for clinicians
Correction to "American Cancer Society's report on the status of cancer disparities in the United States, 2025".
- 1 Mar 2026
- CA: a cancer journal for clinicians
Radiotherapy followed by adjuvant temozolomide improves survival for patients with aggressive IDH-mutated anaplastic glioma.
- 1 Mar 2026
- CA: a cancer journal for clinicians
Targeting tumor suppressor gene co-mutations in EGFR-mutant nonsmall cell lung cancer: How ACROSS2 sharpens the case for early intensification.
- 1 Mar 2026
- CA: a cancer journal for clinicians
Ethical considerations of genetic and genomic testing in pediatric oncology: A narrative review.
- 1 Mar 2026
- CA: a cancer journal for clinicians
Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study.
- 1 Mar 2026
- CA: a cancer journal for clinicians
Nonpharmacologic interventions for managing distress, anxiety, and depression for patients with cancer and their family caregivers: A systematic review and meta-analysis.
- 1 Mar 2026
- CA: a cancer journal for clinicians
Correction to "American Cancer Society's report on the status of cancer disparities in the United States, 2025".
- 1 Mar 2026
- CA: a cancer journal for clinicians